PACIRA BIOSCIENCES INC (PCRX) Fundamental Analysis & Valuation
NASDAQ:PCRX • US6951271005
Current stock price
24.64 USD
-0.26 (-1.04%)
At close:
24.64 USD
0 (0%)
After Hours:
This PCRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PCRX Profitability Analysis
1.1 Basic Checks
- In the past year PCRX was profitable.
- In the past year PCRX had a positive cash flow from operations.
- Of the past 5 years PCRX 4 years were profitable.
- In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
- PCRX's Return On Assets of 0.56% is fine compared to the rest of the industry. PCRX outperforms 79.58% of its industry peers.
- The Return On Equity of PCRX (1.01%) is better than 81.15% of its industry peers.
- PCRX's Return On Invested Capital of 2.67% is amongst the best of the industry. PCRX outperforms 80.63% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 13.11%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.56% | ||
| ROE | 1.01% | ||
| ROIC | 2.67% |
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
1.3 Margins
- The Profit Margin of PCRX (0.97%) is better than 79.58% of its industry peers.
- PCRX's Profit Margin has declined in the last couple of years.
- Looking at the Operating Margin, with a value of 5.33%, PCRX is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
- In the last couple of years the Operating Margin of PCRX has declined.
- With an excellent Gross Margin value of 79.39%, PCRX belongs to the best of the industry, outperforming 84.82% of the companies in the same industry.
- PCRX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.33% | ||
| PM (TTM) | 0.97% | ||
| GM | 79.39% |
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
2. PCRX Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PCRX is destroying value.
- PCRX has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for PCRX has been reduced compared to 5 years ago.
- PCRX has a better debt/assets ratio than last year.
2.2 Solvency
- PCRX has an Altman-Z score of 1.92. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 1.92, PCRX is in line with its industry, outperforming 58.12% of the companies in the same industry.
- The Debt to FCF ratio of PCRX is 2.72, which is a good value as it means it would take PCRX, 2.72 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 2.72, PCRX belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
- PCRX has a Debt/Equity ratio of 0.54. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
- With a Debt to Equity ratio value of 0.54, PCRX is not doing good in the industry: 66.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 2.72 | ||
| Altman-Z | 1.92 |
ROIC/WACC0.31
WACC8.55%
2.3 Liquidity
- A Current Ratio of 4.54 indicates that PCRX has no problem at all paying its short term obligations.
- PCRX has a better Current ratio (4.54) than 61.78% of its industry peers.
- PCRX has a Quick Ratio of 3.28. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- PCRX has a Quick ratio of 3.28. This is comparable to the rest of the industry: PCRX outperforms 54.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.54 | ||
| Quick Ratio | 3.28 |
3. PCRX Growth Analysis
3.1 Past
- The earnings per share for PCRX have decreased strongly by -18.07% in the last year.
- The Earnings Per Share has been growing slightly by 3.64% on average over the past years.
- The Revenue for PCRX has decreased by -16.32% in the past year. This is quite bad
- The Revenue has been growing by 11.08% on average over the past years. This is quite good.
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%
3.2 Future
- The Earnings Per Share is expected to grow by 10.64% on average over the next years. This is quite good.
- PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.42% yearly.
EPS Next Y2.7%
EPS Next 2Y16.4%
EPS Next 3Y20.27%
EPS Next 5Y10.64%
Revenue Next Year4.19%
Revenue Next 2Y6.34%
Revenue Next 3Y8.72%
Revenue Next 5Y5.42%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. PCRX Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 9.37, which indicates a very decent valuation of PCRX.
- Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
- PCRX is valuated cheaply when we compare the Price/Earnings ratio to 27.71, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 9.12 indicates a reasonable valuation of PCRX.
- PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 90.05% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (38.09), we can say PCRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.37 | ||
| Fwd PE | 9.12 |
4.2 Price Multiples
- PCRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PCRX is cheaper than 91.10% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 95.81% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.3 | ||
| EV/EBITDA | 8.19 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PCRX does not grow enough to justify the current Price/Earnings ratio.
- The decent profitability rating of PCRX may justify a higher PE ratio.
- PCRX's earnings are expected to grow with 20.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.47
PEG (5Y)2.58
EPS Next 2Y16.4%
EPS Next 3Y20.27%
5. PCRX Dividend Analysis
5.1 Amount
- PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PCRX Fundamentals: All Metrics, Ratios and Statistics
24.64
-0.26 (-1.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26 2026-02-26/amc
Earnings (Next)04-30 2026-04-30
Inst Owners119.39%
Inst Owner Change0.07%
Ins Owners2.16%
Ins Owner Change16.51%
Market Cap997.67M
Revenue(TTM)726.41M
Net Income(TTM)7.03M
Analysts76.92
Price Target29.29 (18.87%)
Short Float %20.59%
Short Ratio10.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.46%
Min EPS beat(2)-38.21%
Max EPS beat(2)5.28%
EPS beat(4)3
Avg EPS beat(4)-7.2%
Min EPS beat(4)-38.21%
Max EPS beat(4)5.28%
EPS beat(8)6
Avg EPS beat(8)1.27%
EPS beat(12)7
Avg EPS beat(12)-1.33%
EPS beat(16)7
Avg EPS beat(16)-6.57%
Revenue beat(2)0
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-3.7%
Max Revenue beat(2)-3.59%
Revenue beat(4)0
Avg Revenue beat(4)-4.05%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-2.99%
Revenue beat(8)1
Avg Revenue beat(8)-2.33%
Revenue beat(12)1
Avg Revenue beat(12)-2.76%
Revenue beat(16)1
Avg Revenue beat(16)-2.75%
PT rev (1m)-3.37%
PT rev (3m)-3.37%
EPS NQ rev (1m)-1.58%
EPS NQ rev (3m)-21.29%
EPS NY rev (1m)-11.96%
EPS NY rev (3m)-22.79%
Revenue NQ rev (1m)-1.83%
Revenue NQ rev (3m)-6.05%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-3.76%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.37 | ||
| Fwd PE | 9.12 | ||
| P/S | 1.37 | ||
| P/FCF | 7.3 | ||
| P/OCF | 6.56 | ||
| P/B | 1.44 | ||
| P/tB | 3.27 | ||
| EV/EBITDA | 8.19 |
EPS(TTM)2.63
EY10.67%
EPS(NY)2.7
Fwd EY10.96%
FCF(TTM)3.38
FCFY13.7%
OCF(TTM)3.75
OCFY15.23%
SpS17.94
BVpS17.12
TBVpS7.53
PEG (NY)3.47
PEG (5Y)2.58
Graham Number31.8271 (29.17%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.56% | ||
| ROE | 1.01% | ||
| ROCE | 3.38% | ||
| ROIC | 2.67% | ||
| ROICexc | 3.38% | ||
| ROICexgc | 5.91% | ||
| OM | 5.33% | ||
| PM (TTM) | 0.97% | ||
| GM | 79.39% | ||
| FCFM | 18.81% |
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
ROICexc(3y)6.66%
ROICexc(5y)7.23%
ROICexgc(3y)14.37%
ROICexgc(5y)26.99%
ROCE(3y)5.91%
ROCE(5y)6.18%
ROICexgc growth 3Y-17.07%
ROICexgc growth 5Y-17.82%
ROICexc growth 3Y-9.16%
ROICexc growth 5Y-18.82%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
F-Score8
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.54 | ||
| Debt/FCF | 2.72 | ||
| Debt/EBITDA | 2.87 | ||
| Cap/Depr | 16.85% | ||
| Cap/Sales | 2.11% | ||
| Interest Coverage | 2.54 | ||
| Cash Conversion | 117.14% | ||
| Profit Quality | 1942.86% | ||
| Current Ratio | 4.54 | ||
| Quick Ratio | 3.28 | ||
| Altman-Z | 1.92 |
F-Score8
WACC8.55%
ROIC/WACC0.31
Cap/Depr(3y)16.8%
Cap/Depr(5y)48.87%
Cap/Sales(3y)1.96%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
EPS Next Y2.7%
EPS Next 2Y16.4%
EPS Next 3Y20.27%
EPS Next 5Y10.64%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%
Revenue Next Year4.19%
Revenue Next 2Y6.34%
Revenue Next 3Y8.72%
Revenue Next 5Y5.42%
EBIT growth 1Y-65.3%
EBIT growth 3Y-18.29%
EBIT growth 5Y-8.56%
EBIT Next Year0.28%
EBIT Next 3Y34.34%
EBIT Next 5Y7.61%
FCF growth 1Y-23.55%
FCF growth 3Y5.86%
FCF growth 5Y28.37%
OCF growth 1Y-19.75%
OCF growth 3Y1.51%
OCF growth 5Y14.57%
PACIRA BIOSCIENCES INC / PCRX Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
Can you provide the valuation status for PACIRA BIOSCIENCES INC?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
Can you provide the profitability details for PACIRA BIOSCIENCES INC?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 6 / 10.
What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?
The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 7 / 10.